BSX · 8-K · 20261007PR000064
Acquisition / Partnership / Divestiture
BOSTON SCIENTIFIC CORP · 2026-10-07 · Importance 41 · Surprise 42 · In source text
Boston Scientific stated that the Interventional Therapies segment will include the Penumbra business following the anticipated close of the acquisition. Lance Bates, executive vice president and president of Interventional Therapies, will lead the expanded global segment. The release did not disclose the transaction value, expected closing date or any projected financial impact. The Penumbra business will therefore be incorporated into the new operating structure after closing.
Key facts
- The global Interventional Therapies segment will include the Penumbra business following the anticipated close of the acquisition. source
- The press release states the inclusion of the Penumbra business in Interventional Therapies is conditioned on the anticipated close of the acquisition. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | probable | — | The global Interventional Therapies segment will include the Penumbra business following the anticipated close of the acquisition. |
| assets | positive | probable | — | The global Interventional Therapies segment will include the Penumbra business following the anticipated close of the acquisition. |